Abzena PLC (LON:ABZA)‘s stock had its “buy” rating reiterated by research analysts at FinnCap in a report released on Tuesday. They currently have a GBX 100 ($1.24) target price on the stock. FinnCap’s price objective indicates a potential upside of 194.12% from the company’s current price.

Separately, N+1 Singer reaffirmed a “corporate” rating on shares of Abzena PLC in a research note on Thursday, November 24th.

Shares of Abzena PLC (LON:ABZA) opened at 34.00 on Tuesday. Abzena PLC has a 52-week low of GBX 31.00 and a 52-week high of GBX 65.00. The company has a 50-day moving average of GBX 36.83 and a 200 day moving average of GBX 41.69. The firm’s market cap is GBX 46.30 million.

WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2016/12/01/abzena-plc-abza-stock-rating-reaffirmed-by-finncap.html.

About Abzena PLC

Abzena plc is a life sciences company providing services and technologies. The Company is engaged in the provision of services and technology licenses. The Company consists of PolyTherics and Antitope, which have established a suite of services and technologies that are designed to improve the chances of development of antibodies and proteins with therapeutic benefits.

Receive News & Stock Ratings for Abzena PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena PLC and related stocks with our FREE daily email newsletter.